# Introduction:

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter:

Fujirebio Diagnostics, Inc.   
940 Crossroads Blvd   
Seguin, TX 78155   
(830) 372-1391 ex. 210   
Establishment Registration Number: 1643621

# Contact Person:

Kent Pruett

# Device Name:

FDI Glucose Control for Aviva

Common Name:

Single Analyte Control Solution, All Types (Assayed and Unassayed)

# Classification Name:

Quality Control Material (assayed and unassayed).

Classification:

Class I per 21 CFR 862.1660

Product Code:

75 JJX

# Panel:

Chemistry

Predicate Devices:

Name: Manufacturer: 510(k) No.:

# Accu-CHEk Aviva Control Level 1 Roche Diagnostics k043474

# Device Description:

The FDI Glucose Control for Aviva consists of a viscosity-adjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.

Intended Use:

The FDI Glucose Control for Aviva is intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people

# 510(k) Premarket Notification: FDI Glucose Control for Aviva Fujirebio Diagnostics, Inc.

with diabetes mellitus to assess the performance of Accu-CHEk Aviva Blood Glucose Monitor.

# Comparison to Predicate Devices:

<table><tr><td rowspan=1 colspan=1>Characteristic/Aspect</td><td rowspan=1 colspan=1>3Predicate Device No. 1</td><td rowspan=1 colspan=1>New Product&quot;V</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Accu-CHEK Aviva Control Level 1</td><td rowspan=1 colspan=1>FDI Glucose Control for Aviva</td></tr><tr><td rowspan=1 colspan=1>510(k), Date</td><td rowspan=1 colspan=1>K04347404/27/2005</td><td rowspan=1 colspan=1>â€¢</td></tr><tr><td rowspan=1 colspan=1>Number of Levels</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>Glucose</td></tr><tr><td rowspan=1 colspan=1>Target Range (mg/dL)</td><td rowspan=1 colspan=1>25-55{&quot;)</td><td rowspan=1 colspan=1>19-51{2</td></tr><tr><td rowspan=1 colspan=1>Container</td><td rowspan=1 colspan=1>Plastic bottle with dropper-tip</td><td rowspan=1 colspan=1>Plastic bottle with dropper-tip</td></tr><tr><td rowspan=1 colspan=1>Fill Volume</td><td rowspan=1 colspan=1>2.5 mL</td><td rowspan=1 colspan=1>3.6 mL</td></tr><tr><td rowspan=1 colspan=1>Color</td><td rowspan=1 colspan=1>Red</td><td rowspan=1 colspan=1>Red</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Glucose, buffer, salts, non-reactive ingredients,preservative, FD &amp; C Blue #1</td><td rowspan=1 colspan=1>Buffered aqueous solution of D-Glucose, a viscosity modifier,preservatives, and other non-reactive ingredients</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Checks that the meter and teststrips are working properly togive reliable results.</td><td rowspan=1 colspan=1>To check the performance of theAccU-CHEk Aviva Blood GlucoseSystem.</td></tr><tr><td rowspan=1 colspan=1>Target Population</td><td rowspan=1 colspan=1>Professional and home use</td><td rowspan=1 colspan=1>Professional and home use</td></tr></table>

"Derived from the control ranges assigned by the manufacturer. (2)Based on a +/- 5% glucose concentration variability lot-to-lot and +/ 15 mg/dl range

# Performance Studies: characteristics:

Tests were performed to verify specific performance

Real Time Stability Open Vial Stability Test precision

# Conclusion:

Comparison of the performance characteristics, formulation and intended use support the claim of substantial equivalence.

Fujirebio Diagnostics, Inc.   
c/o Kent Pruett   
Director of Quality and Regulatory Affairs 940 Crossroads Blvd.   
Seguin, TX 78155   
Re: k110436   
Trade Name: FDI Glucose Control Solution for Aviva   
Regulation Number: 21 CFR 862.1660   
Regulation Name: single (specified) analyte controls (assayed and unassayed)   
Regulatory Class: Class I, reserved   
Product Codes: JJX   
Dated: February 8, 2011   
Received: February 15, 2011

Dear Mr. Pruett:

1

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for-use stated-in-the enclosure)-to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

GC.

Coukthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

510(k) Premarket Notification: FDl Glucose Control for Aviva Fujirebio Diagnostics, Inc.

# 4 Indications for Use Statement

510(k) Number  k)11

Device Name: FDI Glucose Control for Aviva

Indications for Use:

For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the Aviva Blood Glucose Monitor.

![](images/525b83cf65094f6bc9da99cb25464124e62f64ad88c3ac02846bad99a0f522d3.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) k110436